pembrolizumab biosimilar (Biocon)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug Namepembrolizumab biosimilar (Biocon)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionApoptosis stimulantsProgrammed cell death protein 1 blockersT lymphocytes stimulants +[4] 
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiocon Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiocon Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A